2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaB-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmRecruitingPhase 22025-06-15NCT07022223
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery DiseaseArterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorderActive, not recruitingNot applicable2024-01-23NCT04397211